

Item 8.01. Other Events.

On April 17, 2017, the Company issued two press releases titled “Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study” and “Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan.” A copy of each press release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.

Item 9.01. Financial Statement and Exhibits.

Exhibit No. Description

- | | |
|------|---|
| 99.1 | Press release of Cleveland BioLabs, Inc. dated April 17, 2017 |
| 99.2 | Press release of Cleveland BioLabs, Inc. dated April 17, 2017 |
-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cleveland BioLabs, Inc.

Date: April 17, 2017 By: /s/ YAKOV KOGAN

Name: Yakov Kogan

Title: Chief Executive Officer